Feb 25, 2026
In this episode, we explore the groundbreaking COaST trial examining semaglutide for clozapine-induced weight gain in schizophrenia patients. Could GLP-1 agonists finally offer a real solution to one of psychiatry's most frustrating paradoxes—when the medication that saves lives simultaneously shortens them?
Faculty: Oliver Freudenreich, M.D.
Host: Richard Seeber, M.D.